Bone turnover during high dose inhaled corticosteroid treatment.

Ali, N.J.; Capewell, Simon; Ward, Michael J.

doi:10.1136/thx.46.3.160

Cited by 166 publications

(67 citation statements)

References 20 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only in the study of A li et al were changes found [32]. In this study in 8 healthy volunteers, a small decrease in AP was found after treatment with BDP 2.0 mg/day for 4 weeks, whereas after BUD 1.8 mg/day (n -8) no changes were observed.…”

Section: Side-effects: General Considerationscontrasting

confidence: 55%

“…Markers of bone resorption, such as excretion of calcium and hydroxyprolines in urine, appeared to be increased in one study [32], but were unaltered in most studies [21,25,26,30,31,33,37]. Other markers of bone resorption include type 1 carboxy-terminal telopeptide (1CTP) and (deoxy)pyridinoline cross links [34,39].…”

Section: Biochemical Markers O F Bone Turnovermentioning

confidence: 99%

See 1 more Smart Citation

Effects of inhaled corticosteroids on bone

Bootsma

Dekhuijzen

Festen

et al. 1997

The Netherlands Journal of Medicine

View full text Add to dashboard Cite

Inhaled corticosteroids (ICS) are the most effective therapy for asthma currently available. The increasing use of ICS raises the issue of possible adverse systemic effects. Since one of the most important side-effects of oral corticosteroids (OCS) is osteoporosis, this article focuses on current knowledge of the effects of ICS on bone. Generally, doses higher than 1.0 mg/day cause a dose-dependent decrease in serum osteocalcin levels. Decreases in bone density have been suggested after treatment with ICS, but in most studies it is impossible to quantify the contribution of previous treatment with OCS and other confounding factors to bone loss. The clinical relevance of the observed changes in the long term is unknown. To date,

show abstract

Section: Side-effects: General Considerationscontrasting

confidence: 55%

Section: Biochemical Markers O F Bone Turnovermentioning

confidence: 99%

Effects of inhaled corticosteroids on bone

Bootsma

Dekhuijzen

Festen

et al. 1997

The Netherlands Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…En pacientes asmáticos tratados con esteroides inhalados se ha notificado una disminución de la formación ósea por la reducción del PICP. 28 Kerstjens y colaboradores 10 no comunican diferencias en este marcador, mientras que Crowley y colaboradores 23 informan niveles elevados de PICP y sugieren que los glucocorticoides modifican el aclaramiento del mismo.…”

Section: Discussionunclassified

Efecto de budesonida sobre la densidad y el metabolismo óseo en niños asmáticos

Valeri¹,

Gómez²,

Valeri³

et al. 2000

Salud pública Méx

View full text Add to dashboard Cite

“…Estes esteróides podem estimular a reabsorção óssea diretamente ou ainda indiretamente, através do aumento na secreção do PTH (54). O aumento na excreção urinária de metabólitos de degradação do colágeno (hidroxiprolina, deoxipiridinolina, e telopeptídeos N e C terminal de colágeno tipo I) é uma evidência bioquímica do incremento de reabsorção óssea induzida pelos glicocorticóides (55)(56)(57).…”

Section: Iii) Ação Direta Nas Células óSseasunclassified

Fisiopatologia da osteoporose induzida por glicocorticóide

Lanna

Montenegro

Paula

2003

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOO hipercortisolismo crônico é a causa mais freqüente de osteoporose secundária, acometendo principalmente o osso trabecular. Aproximadamente 30-35% dos pacientes com síndrome de Cushing apresentam fraturas de vértebras por compressão e o risco de fraturas de colo de fêmur é aumentado em 50% nessa população. Vários mecanismos têm sido propostos para explicar a ocorrência de osteoporose nessa condição, como a ação direta dos glicocorticóides nas paratireóides e nas células ósseas, alterações na produção de prostaglandinas, citocinas, interleucinas, alterações na secreção do hormônio do crescimento (GH), do fator insulina símile-I (IGF-I) e esteróides gonadais. Resultados controversos têm sido apresentados quanto à alteração na secreção do PTH nesta situação, onde níveis normais e elevados têm sido descritos. A elevação da secreção de PTH pode ser secundária a distúr -bios do metabolismo mineral induzidos pelo hipercortisolismo, como diminuição na absorção intestinal, aumento da excreção renal de cál -cio, diminuição no número de receptores paratireoideanos para a 1,25(OH) 2 D 3 , anormalidades no limiar de sensibilidade do cálcio ( set point ) para a secreção do PTH e alteração na sua atividade. Nesta revisão, são discutidos diversos aspectos fisiopatológicos e possíveis mecanismos envolvidos na associação entre hipercortisolismo e osteoporose. Chronic hypercortisolism is the most frequent cause of secondary osteoporosis involving mainly trabecular bone. Approximately 30-35% of the patients with Cushing's syndrome present with compression fractures of vertebrae, and the risk of femoral neck fracture is increased in 50% in that population. Several mechanisms have been proposed to explain the association between hypercortisolism and osteoporosis, as the direct action of glucocorticoids in parathyroid glands and bone cells, alterations in the production of prostaglandins, citokines, interleukines, growth hormone (GH), insulin like growth factor I (IGF-I) and gonadal steroids. Contradictory results have been presented in relation to PTH secretion, where normal and high levels have been described. Elevated PTH secretion can occur as a consequence of disturbances in mineral metabolism, i.e. decrease in the intestinal absortion and elevation in the renal excretion of calcium, decrease in the number of parathyroid receptors for 1,25(OH) 2 D 3 , abnormalities in the calcium set point for PTH secretion, and alteration in PTH activity. In this review, several pathophysiologic aspects and possible mechanisms involved in the association between osteoporosis and hypercortisolism are discussed. (Arq Bras Endocrinol Metab 2003;47/1: 9-18)

show abstract

Bone turnover during high dose inhaled corticosteroid treatment.

Cited by 166 publications

References 20 publications

Effects of inhaled corticosteroids on bone

Effects of inhaled corticosteroids on bone

Efecto de budesonida sobre la densidad y el metabolismo óseo en niños asmáticos

Fisiopatologia da osteoporose induzida por glicocorticóide

Contact Info

Product

Resources

About